GSK343: Selective EZH2 Inhibitor for Epigenetic Cancer Research

Executive Summary: GSK343 is a highly selective inhibitor of the histone methyltransferase EZH2, with an in vitro IC50 of 4 nM for EZH2 and 240 nM for EZH1, making it a precise tool for dissecting PRC2 pathway function (APExBIO). It competitively inhibits EZH2 by blocking the S-adenosylmethionine (SAM) binding site, leading to rapid suppression of H3K27 trimethylation in multiple cancer cell models (Lin et al., 2025). GSK343 demonstrates robust anti-proliferative activity in breast (IC50 174 nM for H3K27me3 inhibition in HCC1806) and prostate (LNCaP IC50 2.9 μM) cancer cells. The compound is insoluble in water and ethanol but dissolves readily in DMF (≥7.58 mg/mL, gentle warming), and is best used in vitro due to high clearance in animal models. Its specificity for EZH2 over other methyltransferases minimizes off-target effects, enabling reproducible interrogation of epigenetic gene repression and PRC2-mediated chromatin regulation (aclacinomycina.com).

Biological Rationale

EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2). PRC2 catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), a key epigenetic mark that represses transcription of tumor suppressor genes such as RUNX3, FOXC1, and BRCA1 (Lin et al., 2025). Elevated EZH2 expression and H3K27me3 levels are linked to silencing of antigen presentation and interferon signaling pathways, facilitating immune evasion in many cancers. Targeting EZH2 activity allows researchers to reverse these suppressive marks, reactivate silenced genes, and study the functional consequences on cancer cell fate, immunogenicity, and therapy response. GSK343, developed and supplied by APExBIO, provides a high-affinity, cell-permeable chemical probe for specific EZH2 inhibition, enabling controlled manipulation of epigenetic states in vitro.

Mechanism of Action of GSK343

GSK343 is a SAM-competitive inhibitor, binding to the S-adenosylmethionine cofactor binding pocket of EZH2 (APExBIO). This prevents the transfer of methyl groups to the ε-amino group of lysine 27 on histone H3, sharply reducing H3K27me3 levels. The inhibitory effect is highly specific: GSK343 demonstrates an IC50 of 4 nM for EZH2, and 240 nM for the homologous enzyme EZH1. Off-target activity for other SAM-dependent methyltransferases—including DNMT, MLL, PRMT, and SETMAR—is minimal, enhancing experimental specificity. In breast cancer HCC1806 cells, GSK343 reduces H3K27 trimethylation with an IC50 of 174 nM after 72 hours. By reducing PRC2-mediated gene repression, GSK343 reactivates tumor suppressor pathways and increases cellular susceptibility to apoptosis and autophagy. In HepG2 liver cancer cells, GSK343 also potentiates the antitumor effects of sorafenib (APExBIO).

Evidence & Benchmarks

• GSK343 inhibits EZH2 enzymatic activity with an IC50 of 4 nM under biochemical assay conditions (HEPES buffer, pH 7.5, 25°C, 1 h incubation) (APExBIO).
• EZH1 inhibition by GSK343 is ~60-fold weaker (IC50 240 nM), supporting target selectivity (APExBIO).
• In HCC1806 breast cancer cells, GSK343 reduces H3K27me3 levels with an IC50 of 174 nM after 72 h exposure (APExBIO).
• LNCaP prostate cancer cells exhibit growth inhibition with an IC50 of 2.9 μM following 72 h GSK343 treatment (APExBIO).
• Combination of GSK343 with sorafenib in HepG2 cells enhances apoptosis compared to either agent alone (24 h, 37°C) (APExBIO).
• CBX2 and EZH2, as PRC subunits, cooperatively suppress tumor immunogenicity via histone modification pathways, reinforcing the rationale for EZH2 inhibition as an anti-cancer strategy (Lin et al., 2025).

This article extends prior coverage by integrating latest mechanistic findings from Lin et al. (2025) on PRC-mediated immune evasion and benchmarking GSK343’s selectivity profile in context (see prior lab workflows; our update provides mechanistic underpinnings for observed reproducibility).

Applications, Limits & Misconceptions

GSK343 is primarily used for in vitro studies of EZH2 function and epigenetic gene regulation in cancer cell models. Its high specificity and cell permeability enable effective interrogation of H3K27 trimethylation dynamics, transcriptional repression, and the downstream impact on tumorigenic phenotypes. The compound is widely used in breast and prostate cancer models, as well as in studies of PRC2’s role in immune evasion and therapy resistance.

Common Pitfalls or Misconceptions

• Not suitable for in vivo pharmacology: GSK343 is rapidly cleared in animal models due to high metabolic turnover—its primary application is in vitro (APExBIO).
• Solubility limitations: GSK343 is insoluble in water and ethanol—dissolution in DMF (≥7.58 mg/mL, gentle warming) is required.
• Does not inhibit non-SAM-dependent methyltransferases: GSK343’s selectivity is restricted to SAM-dependent enzymes and is not effective against other classes.
• EZH1 inhibition at higher concentrations: At ≥240 nM, GSK343 may also inhibit EZH1, potentially complicating interpretation where EZH1 is functionally relevant.
• Cell line specificity: Sensitivity varies by cell type; for example, LNCaP cells are highly responsive, but other lines may require titration.

This analysis clarifies boundaries not fully addressed in earlier reviews (dznep.com), by specifying concentration ranges and experimental limitations.

Workflow Integration & Parameters

For in vitro use, dissolve GSK343 in DMF at ≥7.58 mg/mL using gentle warming. Store the solid at -20°C for long-term stability. Typical working concentrations range from 100 nM to 5 μM, depending on cell type and experimental endpoint. Run parallel vehicle controls and consider a 72-hour incubation window for robust H3K27me3 demethylation. For reproducibility, consult lab workflow guides and recent strategic reviews for troubleshooting and optimization in epigenetic assays. This article updates these guides with specific benchmark values and mechanistic rationale.

Conclusion & Outlook

GSK343, as supplied by APExBIO, is a validated, highly selective, and cell-permeable EZH2 inhibitor optimized for in vitro studies of epigenetic regulation in cancer research. Its robust selectivity, reproducibility, and clear mechanistic action on H3K27 trimethylation make it a leading choice for dissecting PRC2 function and chromatin-mediated gene repression. As the landscape of epigenetic therapy and immuno-oncology advances, tools like GSK343 will remain foundational for unraveling the interplay between chromatin state, gene expression, and tumor immune evasion. For detailed protocols and ordering, see the GSK343 product page.